Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Y4DY
|
||||
| Former ID |
DIB013376
|
||||
| Drug Name |
Xylometazoline
|
||||
| Synonyms |
Xylometazoline (nasal mucoadhesive/MucoAd, congestion); Decongestant (nasal mucoadhesive/MucoAd, congestion), Strategic BioSciences; Xylometazoline (nasal mucoadhesive/MucoAd, congestion), Strategic BioSciences
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Allergic rhinitis [ICD9: 472.0, 477, 995.3; ICD10:J00, J30, J31.0, T78.4] | Phase 4 | [1], [2] | ||
| Company |
Fortune Apex Development Ltd
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C16H24N2
|
||||
| InChI |
InChI=1S/C16H24N2/c1-11-8-13(16(3,4)5)9-12(2)14(11)10-15-17-6-7-18-15/h8-9H,6-7,10H2,1-5H3,(H,17,18)
|
||||
| InChIKey |
HUCJFAOMUPXHDK-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 526-36-3
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
10115, 6383463, 7980899, 8153498, 10525289, 11111974, 11111975, 11335333, 11360572, 11363276, 11365838, 11368400, 11371632, 11374042, 11376562, 11461544, 11466251, 11467371, 11484646, 11485922, 11488761, 11490402, 11492197, 11494196, 14823275, 29224746, 47291005, 47440118, 47515181, 47810616, 47810617, 47885277, 47959589, 48259083, 49698391, 49980614, 50100368, 50104259, 50663281, 57322906, 81115495, 85209855, 85789475, 87676529, 90340774, 96025367, 99443248, 103270012, 103936650, 104310028
|
||||
| Target and Pathway | |||||
| Target(s) | Alpha-2C adrenergic receptor | Target Info | Modulator | [3], [4] | |
| KEGG Pathway | cGMP-PKG signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| PANTHER Pathway | Alpha adrenergic receptor signaling pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| Reactome | Adrenoceptors | ||||
| Adrenaline signalling through Alpha-2 adrenergic receptor | |||||
| Adrenaline,noradrenaline inhibits insulin secretion | |||||
| G alpha (i) signalling events | |||||
| G alpha (z) signalling events | |||||
| Surfactant metabolism | |||||
| WikiPathways | Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Platelet Aggregation (Plug Formation) | |||||
| Integration of energy metabolism | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 517). | ||||
| REF 2 | ClinicalTrials.gov (NCT00630474) Nasal Decongestion and Obstructive Sleep Apnea. U.S. National Institutes of Health. | ||||
| REF 3 | Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. | ||||
| REF 4 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.